BioCentury | Jan 5, 2019
Finance

Ready to launch

...cancer (NMIBC) Phase III data Mid-2019 Soligenix Inc. (NASDAQ:SNGX) / SciClone Pharmaceuticals Inc. dusquetide (SGX94, SGX942...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

...include identifying SQSTM1 inhibitors and testing them in SMA models. Soligenix Inc. has dusquetide (SGX94, SGX942...
BioCentury | Aug 11, 2017
Clinical News

Soligenix begins Phase III of dusquetide to treat oral mucositis

...Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat...
...therapy (CRT) for head and neck cancer. Patients receive placebo or twice-weekly 1.5 mg/kg IV dusquetide...
...NASDAQ:SNGX), Princeton, N.J. SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif. Product: Dusquetide ( SGX94 , SGX942...
BioCentury | Dec 14, 2016
Clinical News

Dusquetide regulatory update

...U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to dusquetide...
...Soligenix to treat severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy. Dusquetide...
...p62). Soligenix Inc. (NASDAQ:SNGX), Princeton, N.J. Product: Dusquetide ( SGX94 , SGX942) Business: Other Julian Zhu dusquetide SGX94 SGX942 Soligenix...
BioCentury | Sep 19, 2016
Company News

Soligenix, SciClone deal

...South Korea and Vietnam to a 2013 deal granting SciClone rights to develop and market SGX942...
...to Soligenix’s close of $0.77 on Sept. 9, the day before the deal was announced. SGX942...
BioCentury | Jan 4, 2016
Clinical News

SGX94: Preliminary Phase II data

...in 111 patients undergoing chemoradiation for head and neck cancer showed that 1.5 mg/kg IV SGX942...
...the trial protocol was a p-value of <0.1. In patients receiving the most aggressive chemoradiation, SGX942...
...3 and 6 mg/kg doses of SGX942. Soligenix Inc. (OTCBB:SNGX), Princeton, N.J. Product: SGX94 , SGX942...
BioCentury | Sep 28, 2015
Clinical News

SGX94: Completed Phase II enrollment

...1.5, 3 and 6 mg/kg IV SGX942. Soligenix Inc. (OTCBB:SNGX), Princeton, N.J. Product: SGX94 , SGX942...
BioCentury | Dec 16, 2013
Clinical News

SGX94: Phase II started

...II trial to evaluate SGX942 in patients undergoing chemoradiation therapy for head and neck cancer. SGX942...
...to SGX942 to treat OM (see BioCentury, July 15). Last December, Soligenix acquired rights to SGX942...
...of British Columbia (see BioCentury, Jan. 14). Soligenix Inc. (OTCBB:SNGX), Princeton, N.J. Product: SGX94 , SGX942...
BioCentury | Sep 23, 2013
Clinical News

SGX94 regulatory update

...designation to Soligenix's SGX94 to treat acute radiation syndrome (ARS). Soligenix said preclinical data with SGX94...
...of which occur with varying severity in ARS. SGX942, which is the compound number for SGX94...
...to SGX942 to treat OM (see BioCentury, July 15). Last December, Soligenix acquired rights to SGX942...
BioCentury | Jul 15, 2013
Company News

SciClone, Soligenix deal

...Soligenix granted SciClone Chinese marketing rights to SGX942 to treat oral mucositis (OM). In exchange, SciClone...
...According to Soligenix, data from SciClone could increase the success of Phase II testing of SGX942...
...year end. The companies said specific terms were not disclosed (see BioCentury, March 5, 2012). SGX942...
Items per page:
1 - 10 of 13